Valéry Attignon

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Olivier Trédan, Qing Wang, Daniel Pissaloux et al. · Annals of Oncology · 2019 · 176 citations

Medicine, Patient Selection, Cancer Management +10

Genomics to select treatment for patients with metastatic breast cancer

Fabrice André, Thomas Filleron, Maud Kamal et al. · Nature · 2022 · 157 citations

Metastatic Breast Cancer, Breast Oncology, Tumor Heterogeneity +9

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

Mathilde Small, Isabelle Treilleux, Coline Couillault et al. · Acta Neuropathologica · 2018 · 112 citations

Immunogenetics, Genetic Disorder, Medicine +9

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Jean‐Philippe Foy, Andy Karabajakian, Sandra Ortiz‐Cuaran et al. · European Journal of Cancer · 2022 · 62 citations

Cancer Immunosurveillance, Medicine, Immunology +10